Delivery Order SPE2DR25D1104-SPE2DR26FK873
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $42,368.91 to AmerisourceBergen Drug Corp for RINVOQ ER 30 MG tablets (30-count units) on July 23, 2025, with an ultimate completion date of July 24, 2025. This firm fixed price, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $3,578.79 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count unit dose) on September 9, 2025, with completion expected by September 10, 2025. This non-competitive, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be...
- The Defense Logistics Agency awarded a delivery order valued at $9,334.98 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose packages) on October 27, 2025, with completion targeted for October 28, 2025. This is a firm fixed price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (contract number SPE2DX). The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) with a ceiling value of $7,596.31. This non-competitive, firm fixed-price delivery order was awarded on August 26, 2025, with an ultimate completion date of August 27, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania served as the place of performance. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $40,365.01 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on November 13, 2025, with an ultimate completion date of November 14, 2025. This firm fixed-price, non-set-aside contract was awarded competitively and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order valued at $26,892.34 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The place of performance is Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $22,423.24 to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count bottles) on December 9, 2025, with an ultimate completion date of December 10, 2025. This firm fixed-price, non-set-aside delivery order was issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive global pharmaceutical support vehicle running through December 2026....
- The Defense Logistics Agency awarded a $50,518.58 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 20, 2025, with an ultimate completion date of June 23, 2025. This non-set-aside competitive award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The delivery will be performed at...
- The Defense Logistics Agency awarded a $10.77K delivery order to AmerisourceBergen Drug Corp on December 30, 2025, for RINVOQ ER 30 mg tablets (30-count units). This is a firm fixed-price delivery order with an ultimate completion date of December 31, 2025, representing a competitive award with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count unit dose) valued at $3,111.66 under a firm fixed-price contract. The award, announced on August 6, 2025, with an ultimate completion date of August 7, 2025, represents a non-competitive, non-set-aside delivery order. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order falls...
- SPE2DR25D1104Indefinite Delivery Contract
- SPE2DR25D1104-SPE2DR26FK873Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $32,674.07 to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on January 7, 2026, with an ultimate completion date of January 8, 2026. This firm fixed-price contract, which was not set aside for any specific business classification, represents a task order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (designated SPE2DX). The parent company, Cencora, Inc. (doing business as AmerisourceBergen), holds the primary IDC valued at up to $1 billion through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling delivery of a broad range of medications, vaccines, and medical supplies to military healthcare systems worldwide. Performance of this delivery order will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. RINVOQ (upadacitinib) is a Janus kinase inhibitor used primarily for treating rheumatoid arthritis and other inflammatory conditions within the military healthcare system. This delivery order reflects the routine procurement of essential pharmaceutical commodities under the established IDC framework, demonstrating AmerisourceBergen's critical role as a major pharmaceutical distributor for federal medical procurement needs, particularly supporting the Defense Health Agency and other military treatment facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $32.7k | 1/6/26 |